Iksuda's IKS014 shows 50% response rate in small trial subset of previously treated breast cancer patients

By Public Technologies
  • Iksuda Therapeutics will present preliminary Phase 1 results for IKS014 in HER2-positive solid tumors at the San Antonio Breast Cancer Symposium, December 9, 2026.
  • The treatment showed promising antitumor activity, including in heavily pretreated breast cancer patients who previously received Enhertu.
  • Safety findings indicated manageable side effects, with no treatment-related serious adverse events or fatal events reported.
  • Enrollment continues in expansion cohorts, including breast cancer patients previously treated with Enhertu; the presentation will include updated results.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IP Group plc published the original content used to generate this news brief on November 02, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.